> News & Announcements > FDA Approves First and Only Single-Dose Therapy for Adult Women with Bacterial Vaginosis
In the News
FDA Approves First and Only Single-Dose Therapy for Adult Women with Bacterial Vaginosis
FDA approves Symbiomix Therapeutics’ Solosec for treating BV.
October 2, 2017
Symbiomix Therapeutics today announced the U.S. Food and Drug Administration (FDA) has approved Solosec™ (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. Solosec™ is a potent, next-generation, 5-nitroimidazole antibiotic with enhanced pharmacokinetic properties that enable delivery in a single dose that’s been shown to be efficacious and well tolerated. Solosec™ is the first and only single-dose oral therapy for BV, the most common gynecologic infection in the U.S.